Jennifer M. Jaskowiak
About Jennifer M. Jaskowiak
Jennifer M. Jaskowiak is a Medical Affairs professional at Novocure with extensive experience in patient advocacy, strategic alliances, and oncology.
Current Role at Novocure
Jennifer M. Jaskowiak is currently engaged in Medical Affairs at Novocure. Her work involves overseeing medical initiatives, contributing to strategic planning, and ensuring the delivery of innovative treatment solutions to patients. She leverages her extensive background in the medical field to support Novocure's mission and development projects.
Previous Experience at Champions Oncology, Inc.
From 2015 to 2019, Jennifer served as the Medical Affairs Director, Strategic Alliances and Partnerships at Champions Oncology, Inc. During her tenure, she managed strategic alliances and developed partnerships critical to advancing oncology treatment options. Her role required close collaboration with internal and external stakeholders to foster innovation and implement effective strategies.
Consultant at Valeo Partners
In 2014-2015, Jennifer worked as a Life Sciences Consultant at Valeo Partners in the Washington D.C. Metro Area. Her consultancy focused on providing strategic advice to life sciences companies, particularly in areas related to product development and market positioning. Her insights facilitated better decision-making and project alignment within the companies she consulted for.
Educational Background
Jennifer holds an MBA in International Business from Schiller International University Heidelberg Campus, completed between 1995 and 1997. Additionally, she earned a BA in Chemistry from Virginia Tech, equipping her with a strong scientific and business foundation necessary for her career in the life sciences industry.
Specialization in Rare Diseases and Oncology
Specializing in rare diseases and oncology, Jennifer has extensive experience in strategic alliances, particularly industry-academic partnerships. Her work often involves liaising between different organizations to facilitate the development of groundbreaking treatments. This specialization is complemented by her background in patient advocacy, which informs her approach to drug development and patient engagement.